Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Investor Presentation (December 2021)
32 slides from Jubilant Ingrevia's investor presentation, Dec 13, 2021
Slide 1: Intimation of Investor/Analyst Meetings
December 13, 2021 BSE Limited National Stock Exchange of India Limited P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Dear Sirs, Sub.: Intimation of Investor/ Analyst Meetings Pursuant to the provisions of Regulation 30 of the Securities
Slide 2: List of Investors
List of Investors Investors ASIAMIN Capital Advisors Pte Ltd AUM Fund Advisors LLP Avagrah Capital Chattisgarh Investment Credent Alpha DS Investments Green Lantern Capital LLP Hero Investment Office Holy Basil Consultancy Private Limited ITI Alternate Funds Management Limited Joint vision ventures
Slide 3: Investor Presentation November 2021
Investor Presentation November 2021
Slide 4: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod
Slide 5: Jubilant Ingrevia: Glorious Four Decades of Growth
Jubilant Ingrevia: Glorious Four Decades of Growth Our Journey 10+ years experience in 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ Vitamin B3 Demerger into 2017: Certified for Responsible Care (RC) 2021 new entity 20
Slide 6: Business Segments & Integrated Operations
Business Segments & Integrated Operations Integrated Operations… Vertical integration across the value chain enables cost competitive advantage Nutrition & For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline Speciality Nutrition & Health Life Science Health Solutions (Ke
Slide 7: Executive Leadership Team
Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 34 years of industry experience Anil Khubchandani Chandan Singh Sumit Das Ashish Kumar Sinha President – President – SVP – Nutrition & VP – Animal & Human Speciality Chemicals Life Science Chemicals Health Ingred
Slide 8: Jubilant Ingrevia: Company Snapshot
Jubilant Ingrevia: Company Snapshot Leadership Revenue Segmentation: By Region (FY’21) Total 1400+ customers - Globally # 1 in 11 Pyridine Derivatives • Speciality Chemicals: 420 - Amongst top 2 Globally in (Pyridine + Beta) Domestic Sales • Nutrition & Health Solutions: 400 for International • Life
Slide 9: Strong Presence in Industry Value Chain
Strong Presence in Industry Value Chain CDMO Services Commercial Scale Clinical Phase Manufacturing Intermediates / Discovery Process Development API Formulation Phase I / II / III Custom Manufacturing • Route Design, Process • Phase III: 4 Intermediates for Anti-Viral Jubilant Ingrevia’ s familiari
Slide 10: End Usage Applications for Pharma, Agrochemicals & Nutraceuticals
End Usage Applications for Pharma, Agrochemicals & Nutraceuticals Therapeutic Category Our Product Category (GMP & Non-GMP) (Used in ~ 53 APIs) Pyridine, Picolines Amino Methyl Chloro/ Bromo/ Pyridines Fluoro Pyridines Antipyretic Analgesic Antifibrosis Off- Patented Amino Pyridines Hydroxy Methyl P
Slide 11: Industry Overview: Presence in Large & Growing Markets
Industry Overview: Presence in Large & Growing Markets1 Global Speciality Chemicals Global API Market CAGR 6.4% CAGR 5.8% $ 910 Bn $ 1240 Bn $ 197 Bn $ 262 Bn Speciality FY'21 FY 26 P FY'21 FY'26 P Chemicals Indian Speciality Chemicals Indian API Market CAGR 12.4% CAGR 7.9% $ 41 Bn $ 72 Bn $ 4 Bn $
Slide 12: Overall Expansion Plan: Jubilant Ingrevia
Overall Expansion Plan: Jubilant Ingrevia JVL: Jubilant Ingrevia Limited Plan to double the Revenue by FY’26 from the base of FY’21. Key Projects Capacity Build Up for Growth starting during next 3 years (Quarter in which production is starting) Available Capacity & Expansion Plan (CAGR: 8.3%) 90% 9
Slide 13: Rationale for Investment
Rationale for Investment Proposed Investment Rationale for Investment New facility for launch of 6 Diketene derivatives. Subsequently, Forward integration of our Ketene capability and growing demand of add 8 value-added Diketene derivatives Diketene derivatives globally as well as Import replacement
Slide 14: Business Segments
BUSINESS SEGMENTS
Slide 15: Speciality Chemicals – Segment Snapshot
Speciality Chemicals – Segment Snapshot Region wise Revenue Segmentation (FY’21) FY’21 Capacity Utilisation: 74% 85 Products Amongst top 2 (Pyridines & Globally lowest Domestic Sales Capacity Growth in FY’22 Capacity Growth in FY’23 Globally in Japan,3% Picolines, cost producer of for International
Slide 16: Nutrition & Health Solutions – Segment Snapshot
Nutrition & Health Solutions – Segment Snapshot Revenue Segmentation (FY’21) FY’21 Capacity Utilisation: 70% 5 Nutrition 100% in-house Global top 2 in By Region Ingredients & sourcing of Beta By End use Capacity growth in FY’22 Capacity growth in FY’23 Vitamin B3 Domestic Sales for 18+ branded Picol
Slide 17: Life Sciences Chemicals – Segment Snapshot
Life Sciences Chemicals – Segment Snapshot Region wise Revenue Segmentation (FY’21) FY’21 Capacity Utilisation: 69% 8 Products Leadership in Among top For Segment For Acetic Anhydride merchant market Capacity growth in FY’22 Capacity growth in FY’22 (Acetic Anhydride, suppliers of Domestic Sales for
Slide 18: Multi Location Manufacturing & Operation Excellence
Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, Maharashtra, India Speciality Chemicals, Life Science Chemicals
Slide 19: Jubilant Ingrevia: Global Accreditation
Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath Responsible Care RC 14001:2015 ISO 9001:2015 ISO 22000:2005 ISO 14001:2015 ISO 45001:2018 FSSAI FAMI-QS HALAL KOSHER GMP State State FDA G
Slide 20: Business Excellence and Digital Transformation
Business Excellence and Digital Transformation Belt Competencies (FY’21) Digital Transformation Black Belts: 08 Green Belts: 98 Yellow Belts: 141 Our journey started in 2018 with an objective to improve Business Excellence Operational efficiency Tools & Processes Business & Supply chain proces
Slide 21: Research Development & Technology (RDT)
Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 90 highly qualified scientists (~20 PhDs) 60+ Products in Pipeline for next 5 y
Slide 22: CSR - Jubilant Bhartia Foundation
CSR - Jubilant Bhartia Foundation Mission: To develop multi-stakeholder sustainable models to bring about Established ‘social change’ involving knowledge generation & sharing, experiential in 2007 learning & entrepreneurial ecosystem *A sister organization of World Economic Forum*in Partnership with
Slide 23: Sustainability Journey
Sustainability Journey Our Sustainability Journey Responsible SDG: Key Achievements ESG Assessment care policy First Product 37% Reduction in Specific Water Life Cycle 2014 Consumption wrt FY’13 UNGC Assessment Signatory & Climate Change Participation 2012 27% Reduction in Specific Mitigation & in C
Slide 24: Financials
Ly, JUBILANT \UINGREVIA Financials
Slide 25: Financial Highlights: Key Financial Parameters
Financial Highlights1 : Key Financial Parameters Highlights ₹ 1,223 Cr. ₹ 202 Cr. 16.5% ₹ 111 Cr. 9.1% ₹ 7.0 Q2’FY22 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 56% YoY 44% YoY (135) bps 43% YoY (79) bps 43% YoY Highlights ₹ 784 Cr. ₹ 140 Cr. 17.9% ₹ 77 Cr. 9.9% ₹ 4.8 Q2’FY21 2 Sales EBITDA EBITDA (%) P
Slide 26: Jubilant Ingrevia – Q2'FY22 Financial Highlights
Jubilant Ingrevia – Q2'FY22 Financial Highlights Particulars1 Q2'FY212 Q2'FY22 YoY (%) • Revenue grew by 56% on YoY basis, driven by robust growth in volume and prices. Revenue • Speciality Chemicals revenue grew by 17% YoY driven by volume growth across Speciality Chemicals 252 295 17% product segm
Slide 27: Jubilant Ingrevia – H1'FY22 Financial Highlights
Jubilant Ingrevia – H1'FY22 Financial Highlights Particulars1 H1'FY212 H1'FY22 YoY (%) • Revenue grew by 56% on YoY basis, driven by robust growth in volume and prices. Revenue • Speciality Chemicals revenue grew by 18% YoY driven by volume growth across Speciality Chemicals 509 600 18% product segm
Slide 28: Debt Profile – As on 30th September, 2021
Debt Profile – As on 30th September, 2021 Particulars1 31-Mar-21 30-Jun-21 30-Sep-21 Long Term Borrowings 548 227 218 Short Term Borrowings - 230 45 Total Gross Debt 548 457 263 Cash & Equivalent 117 70 70 Total Net Debt 431 386 193 QoQ change -10% -50% Gross Debt and Net Debt reduction of Rs 193
Slide 29: Balance Sheet – Key Parameters/Ratios (Pro-Forma)
Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 2.0x 2.8x 26.6% 33.2% 16.0% 20.2% 9.4% (%age) (%age) (%age) 16.4% FY'21 H1'FY22 FY'21 H1'FY22 FY'21 H1'FY22 FY'21 H1'FY22 FY'21 H1'FY22 Asset / Turnover FY
Slide 30: Our Vision, Values, Promise and Philosophy
Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing
Slide 31: Thank you for your time
For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1000 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma
Slide 32: Appendix: Income Statement – Q2 & H1'FY22
Appendix : Income Statement – Q2 & H1’FY22 1 2 2 Particulars Q2'FY21 Q2'FY22 YoY (%) H1'FY21 H1'FY22 YoY (%) Total Revenue from Operations 784 1,223 56% 1,520 2,367 56% Speciality Chemicals 252 295 17% 509 600 18% Nutrition & Health Solutions 125 179 43% 274 346 26% Life Science Chemicals 406 749 84
Jubilant Ingrevia — Investor Presentation (December 2021) on 6ix